RTTR - Ritter Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.2548
-0.0059 (-2.26%)
At close: 3:56PM EST
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.2607
Open0.2500
Bid0.2000 x 1100
Ask0.0000 x 1000
Day's Range0.2457 - 0.2583
52 Week Range0.2300 - 1.3500
Volume291,566
Avg. Volume971,904
Market Cap2.458M
Beta (3Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives

    LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, announced that it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. Potential strategic alternatives that may be explored or evaluated by the Company as part of this process include an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions involving the Company.

  • GlobeNewswire

    Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

    LOS ANGELES, Sept. 12, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that.

  • GlobeNewswire

    Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update

    LOS ANGELES, Aug. 14, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that.

  • GlobeNewswire

    Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal (GI) diseases, today announced the appointment of Anthony J. Lembo, M.D., to its Medical Advisory Board. “We are fortunate to have Dr. Lembo, who will be an invaluable resource, join our Medical Advisory Board,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

  • GlobeNewswire

    Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, yesterday reviewed recent market research based on in-depth interviews (n=44)1 and quantitative surveys (n=1,504)2 of patients and physicians, showing the unmet need amongst lactose intolerance (LI) sufferers and interest in new treatment options from both patients’ and physicians’ perspectives. The call was hosted by Andrew J. Ritter, Ritter Pharmaceuticals’ CEO, and Daniel P. Lundberg, Founder and former Chief Marketing Officer at Vivelix Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals.

  • GlobeNewswire

    Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that Daniel P. Lundberg, Founder and former Chief Marketing Officer at Vivelix Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals, will join Ritter Pharmaceuticals’ CEO, Andrew J. Ritter, to present new insights and market research on the lactose intolerance (LI) market. The conference call will be held on August 7, 2019 at 1:30 PM ET/10:30 AM PT.

  • GlobeNewswire

    Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that it has received written notice from Nasdaq that the Company’s minimum bid price deficiency has been cured and that the Company is in compliance with all applicable listing standards. Accordingly, the scheduled hearing before the Hearings Panel to appeal the previous determination of non-compliance has been cancelled.

  • GlobeNewswire

    Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the last patient has completed their final visit in the Company’s first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of lactose intolerance (LI), a study known as “Liberatus” (NCT03597516). The 557-subject clinical trial began enrollment in late June 2018 and completed on-time in just over a year.

  • GlobeNewswire

    Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first Food and Drug Administration (FDA)-approved treatment for lactose intolerance (LI), today provided an update of its Phase 3 clinical trial and regulatory efforts.

  • GlobeNewswire

    Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today shared data from an independent research study conducted by JJN Consulting. The study included a survey of approximately 1,500 LI patients to gain deeper insights into their experiences and into the unmet needs apparent in LI today.

  • GlobeNewswire

    Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

    LOS ANGELES, May 14, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that.

  • GlobeNewswire

    Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the final patient in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of Lactose intolerance (LI), a study known as the “Liberatus” study (NCT03597516), has completed the 30-day treatment dosing period. “We are excited to announce that the last of the 557 enrolled patients in our Liberatus trial has completed dosing and we remain on track for data readout in early Q4 2019,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

  • GlobeNewswire

    Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update

    LOS ANGELES, March 29, 2019 -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the.

  • GlobeNewswire

    Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), a condition afflicting more than 40 million people in the United States and millions more worldwide, today announced that it has completed, ahead of schedule, enrollment in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study (NCT03597516). “We are encouraged and pleased to have achieved this important milestone ahead of schedule.

  • GlobeNewswire

    Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase 3 Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today recaps remarks made by Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan in an expert call hosted by the Company.

  • GlobeNewswire

    Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan will be the subject of an expert call to be held on February 20, 2019 at 1:00 PM ET/10:00 AM PT.

  • GlobeNewswire

    Ritter Pharmaceuticals To Present at Noble Capital Markets’ Fifteenth Annual Investor/Equity Conference on January 28, 2019

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Andrew Ritter, CEO, will be a featured presenter at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference on January 28th at the W Hotel, Fort Lauderdale, Florida. Mr. Ritter will provide an overview of the company's Phase 3 program in lactose intolerance, including its pivotal Phase 3 trial, “Liberatus” which is currently underway, and other important business highlights.

  • GlobeNewswire

    Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

    Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that it has passed the 50 percent enrollment point in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of LI, a study known as the “Liberatus” study. “We are pleased to have achieved this important milestone in study enrollment and we remain on track with our projected timeline for the completion of the Liberatus study in the second half of 2019,” said Andrew J. Ritter, CEO of Ritter Pharmaceuticals.

  • GlobeNewswire

    Consolidated Research: 2018 Summary Expectations for E*TRADE Financial, Ballantyne Strong, Lincoln Educational Services, Electro-Sensors, Capital Southwest, and Ritter Pharmaceuticals — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.